{"id":732789,"date":"2023-02-21T02:03:21","date_gmt":"2023-02-21T07:03:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/"},"modified":"2023-02-21T02:03:21","modified_gmt":"2023-02-21T07:03:21","slug":"verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/","title":{"rendered":"Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LONDON and RALEIGH, N.C., Feb.  21, 2023  (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, March 7, 2023 and host an investment community conference call at 9:00 a.m. EST \/ 2:00 p.m. GMT to discuss these financial results and provide a corporate update.<\/p>\n<p align=\"justify\">To participate, please dial one of the following numbers and ask to join the Verona Pharma call:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">+1-833-816-1396 for callers in the United States<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">+1-412-317-0489 for international callers<\/li>\n<\/ul>\n<p align=\"justify\">A live webcast will be available on the Events and Presentations link on the Investors page of the Company\u2019s website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4GWXJtPRz7hDeex6300ljj-ArmE2QO7x88sElAim0mQiiRr2yIUgetJhSLFTE_-DT0PMVC6wA9XjVkYPI8_DwJAHuYNNM1dHYletcdw-ktk=\" rel=\"nofollow noopener\" target=\"_blank\">www.veronapharma.com<\/a>, and the audio replay will be available for 90 days.<\/p>\n<p>For further information please contact:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Verona Pharma plc<\/strong>\n          <\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">US Tel: +1-833-417-0262<br \/>UK Tel: +44 (0)203 283 4200<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Victoria Stewart, Senior Director of Investor Relations and Communications<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <a href=\"mailto:IR@veronapharma.com\" rel=\"nofollow noopener\" target=\"_blank\">IR@veronapharma.com<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Argot Partners<\/strong><br \/>\n            <br \/>(US Investor Enquiries)<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Tel: +1-212-600-1902<br \/><a href=\"mailto:verona@argotpartners.com\" rel=\"nofollow noopener\" target=\"_blank\">verona@argotpartners.com<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Kimberly Minarovich \/ Carrie McKim<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Optimum Strategic Communications<\/strong><br \/>\n            <br \/>(International Media and European Investor Enquiries)<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Tel: +44 (0)203 882 9621<br \/><a href=\"mailto:verona@optimumcomms.com\" rel=\"nofollow noopener\" target=\"_blank\">verona@optimumcomms.com<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Mary Clark \/ Richard Staines \/ Zoe Bolt<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong><br \/>\n          <br \/>About Verona Pharma<\/strong>\n      <\/p>\n<p align=\"justify\">Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma\u2019s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company has evaluated nebulized ensifentrine in its Phase 3 clinical program ENHANCE (\u201cEnsifentrine as a Novel inHAled Nebulized COPD thErapy\u201d) for COPD maintenance treatment. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine significantly reduced the rate and risk of COPD exacerbations in pooled analysis from ENHANCE-1 and ENHANCE-2. Two additional formulations of ensifentrine have been evaluated in Phase 2 studies for the treatment of COPD: dry powder inhaler (\u201cDPI\u201d) and pressurized metered-dose inhaler (\u201cpMDI\u201d). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4GWXJtPRz7hDeex6300ljnqWmh24Ok2aKay9G_6MAkirOyaQdTNWexwqHEzLdY5L4_IQ3B2ZErfkEMMJhmRon-ZcQX36nubIzQrJk28YWmM=\" rel=\"nofollow noopener\" target=\"_blank\">www.veronapharma.com<\/a>.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MTg5NyM1NDE1Mjc5IzIwODQzNjA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjM4OTliMTMtYjMwNS00MzQ4LTg5NzEtMjc4N2UzMWQ2NzBmLTEwOTU5MzE=\/tiny\/Verona-Pharma-plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON and RALEIGH, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, March 7, 2023 and host an investment community conference call at 9:00 a.m. EST \/ 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-833-816-1396 for callers in the United States +1-412-317-0489 for international callers A live webcast will be available on the Events and Presentations link on the Investors &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-732789","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON and RALEIGH, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, March 7, 2023 and host an investment community conference call at 9:00 a.m. EST \/ 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-833-816-1396 for callers in the United States +1-412-317-0489 for international callers A live webcast will be available on the Events and Presentations link on the Investors &hellip; Continue reading &quot;Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-21T07:03:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MTg5NyM1NDE1Mjc5IzIwODQzNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update\",\"datePublished\":\"2023-02-21T07:03:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\\\/\"},\"wordCount\":385,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MTg5NyM1NDE1Mjc5IzIwODQzNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\\\/\",\"name\":\"Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MTg5NyM1NDE1Mjc5IzIwODQzNjA=\",\"datePublished\":\"2023-02-21T07:03:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MTg5NyM1NDE1Mjc5IzIwODQzNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc1MTg5NyM1NDE1Mjc5IzIwODQzNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update - Market Newsdesk","og_description":"LONDON and RALEIGH, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, March 7, 2023 and host an investment community conference call at 9:00 a.m. EST \/ 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-833-816-1396 for callers in the United States +1-412-317-0489 for international callers A live webcast will be available on the Events and Presentations link on the Investors &hellip; Continue reading \"Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-21T07:03:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MTg5NyM1NDE1Mjc5IzIwODQzNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update","datePublished":"2023-02-21T07:03:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/"},"wordCount":385,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MTg5NyM1NDE1Mjc5IzIwODQzNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/","name":"Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MTg5NyM1NDE1Mjc5IzIwODQzNjA=","datePublished":"2023-02-21T07:03:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MTg5NyM1NDE1Mjc5IzIwODQzNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc1MTg5NyM1NDE1Mjc5IzIwODQzNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=732789"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732789\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=732789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=732789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=732789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}